Good news, Bensocatib Trials Continue for Bronchieactasis

Posted by harrynsc @harrynsc, May 28 5:32pm

For non-cystic fibrosis bronchiectasis
New drug; new mechanism
Insmed company

https://www.investors.com/news/technology/insmed-stock-non-cystic-fibrosis-bronchiectasis-brensocatib/?src=A00220

Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.

becleartoday | @becleartoday | Jun 3 1:45pm

In reply to @lweirdo1 "Any of these available??" + (show)

No, not at this time.

bsi15 | @bsi15 | Jul 30 10:32am

this is probably what some top-experts are referring to
in a recent comment :

Chalmers,Goeminne,Ringshausen,
World Bronchiectasis Conference 2024,
This is a time of great progress and change in the field of bronchiectasis.
A new generation of anti-inflammatory therapies such as dipeptidyl
peptidase-1/cathepsin C
inhibitors are in advanced clinical development [2],

becleartoday | @becleartoday | Jul 30 10:36am

Yes! As well as other exciting treatments🩵

bsi15 | @bsi15 | Aug 20 1:10pm

In reply to @bsi15 "this is probably what some top-experts are referring to in a recent comment : Chalmers,Goeminne,Ringshausen, World..." + (show)

Results showed that a 10 milligram dose of brensocatib
reduced the annualized rate of pulmonary exacerbations by
21.1% versus placebo, while a 25 milligram dose led to a 19.4% reduction.

breakthrough research
past 15 years.
significant reductions in pulmonary exacerbations
James Chalmers, "I am thrilled that the ASPEN ...
This is a great day for patients.”

looks like the typical advertisement exaggerations to me
just 20% fewer exacerbations - not a game-changer

so with BSI=15 my life expectancy goes up from
maybe 5 to 6 years
due to Brensocatib